01 · Seed
NanoAMi · Evidence by component
What supports each part of NanoAMi?
The biological argument is tissue-informed, but the evidence is not equally direct for every part. Here the fibroblast-rich Seed, collagen Soil and platelet-rich-fibrin Signal are assessed separately before the combined protocol is considered.
Reviewed byProfessor Paul Lee MBBch, FRCS (Tr & Orth), PhDCartilage and joint preservation expertiseQuick answer
NanoAMi uses autologous fibroblast-rich micrografts, an injectable type-I collagen scaffold and platelet-rich fibrin. The strongest support is for the biological concepts and individual components; there is no direct human trial of the complete non-operative protocol.
Verified across three networks
Trusted by patients on Doctify, Google and Top Doctors
A transparent evidence map
Three components. Three evidence questions.
Each part is assessed against the meniscus target. Evidence for one component is never presented as proof of the complete protocol.
02 · Soil
Type-I collagen scaffold
03 · Signal
Platelet-rich fibrin
01 · Seed
Autologous fibroblast-rich micrografts
A small hair-follicle-bearing tissue sample is mechanically processed on the day into an autologous micrograft suspension containing fibroblast-rich dermal tissue and native matrix.
How directly does the evidence apply?
Hair-follicle niches contain dermal precursor populations with neural-crest-like properties and multi-lineage potential under laboratory conditions. Human meniscus contains fibroblast-like and fibrochondrocyte populations. These findings make the biological bridge plausible; they do not show that chair-side hair-follicle micrografts regenerate a human meniscus.
Mechanistic evidenceLineage-tracing and laboratory study.
Hair-follicle dermal precursors from distinct developmental origins
Jinno H et al. Stem Cells. 2010;28(11):2027–2040.
Follicle-associated dermal precursors from face and trunk had different developmental origins but similar neural-crest-like properties and multi-lineage behaviour.
Why it belongs here: Supports the choice of the donor niche and corrects the over-broad claim that every hair-follicle cell is neural-crest-derived. It is not meniscus treatment evidence.
Read the published sourceTarget-tissue evidenceHuman cell isolation and in-vitro collagen-scaffold study.
Human meniscus cells include fibroblast-like populations
Nakata K et al. Clinical Orthopaedics and Related Research. 2001;(391 Suppl):S208–S218.
Cells isolated from human meniscus included elongated fibroblast-like cells and attached to a porous collagen scaffold while expressing meniscal matrix genes.
Why it belongs here: Supports the fibroblast and collagen biology of the target tissue, but does not test hair-follicle micrografts or a percutaneous NanoAMi treatment.
Read the published source02 · Soil
Injectable type-I collagen scaffold
A three-dimensional type-I collagen framework intended to retain the delivered biology at the selected meniscus target.
How directly does the evidence apply?
Human meniscus cells have been studied on type-I collagen scaffolds, and a different meniscus-specific collagen implant has clinical trial evidence. Professor Lee currently selects ChondroFiller as the injectable scaffold, but its published product evidence is in articular cartilage—not non-operative meniscus treatment.
Mechanistic evidenceHuman in-vitro cell and scaffold study.
Human meniscus cells on type-I collagen scaffolds
Adesida AB et al. PLoS ONE. 2012;7(6):e39365.
Human meniscal fibrochondrocytes formed matrix after culture on a collagen scaffold, with phenotype affected by culture conditions.
Why it belongs here: Target-tissue support for a collagen scaffold concept; not a study of the chosen injectable product or of NanoAMi.
Read the published sourceIndirect evidenceRandomised controlled trial involving 311 patients.
Collagen meniscus implant compared with partial meniscectomy
Rodkey WG et al. Journal of Bone and Joint Surgery Am. 2008;90(7):1413–1426.
A meniscus-specific collagen implant was assessed as a surgical scaffold after loss of meniscal tissue.
Why it belongs here: Supports the broader meniscus-scaffold principle only. The implant, surgery and indication are not ChondroFiller or NanoAMi.
Read the published source03 · Signal
Autologous platelet-rich fibrin
A preparation made from the patient’s blood that adds a fibrin matrix and platelet-derived biological signals to the combined pathway.
How directly does the evidence apply?
Professor Lee’s selected PRF preparation, ArthroZheal, has meniscus-specific clinical reporting, but in arthroscopic pathways rather than stand-alone non-operative treatment. Broader PRF and PRP studies also concern different preparations or surgical augmentation. None proves NanoAMi.
Target-tissue evidenceComparative cohort of 120 knees; no group without ArthroZheal.
ArthroZheal in arthroscopic meniscus treatment
Skarpas G et al. Surgical Technology International. 2024;44.
Short-term clinical and MRI outcomes were reported after ArthroZheal with meniscoplasty, with or without sutures.
Why it belongs here: Exact-product, target-tissue evidence, but used during surgery and without a non-ArthroZheal control.
Read the published sourceIndirect evidenceTen-patient case series; no control group.
Percutaneous PRP for degenerative meniscus lesions
Blanke F et al. Muscles, Ligaments and Tendons Journal. 2015;5(3):162–166.
Six patients reported improved pain and activity; four later proceeded to surgery.
Why it belongs here: Relevant to non-operative meniscus injection, but uses PRP rather than ArthroZheal PRF and does not include Seed or Soil.
Read the published sourceThe combined protocol
Clinical innovation, with the evidence boundary kept visible
NanoAMi is Professor Lee’s clinician-developed technique for combining fibroblast-rich micrografts, collagen support and an autologous signal. In the standard pathway described on this site it is delivered percutaneously without an operation, arthroscopy or stitches. It requires direct prospective evaluation rather than borrowed certainty from its components.
Progress sometimes begins by bringing established biological principles together before the combination has a mature evidence base of its own. Years of research, operating experience and familiarity with the component parts provide a serious basis for innovation. They are also the reason to state the remaining uncertainty precisely, rather than hide it behind a broad claim.
Questions about the NanoAMi evidence
Has the complete non-operative NanoAMi protocol been clinically proven?
No direct comparative trial of the complete named protocol was located. Fibroblast-rich donor tissue, collagen scaffolds and blood-derived biological signals each have relevant research, but much of it comes from laboratory work, surgery, different products or standalone injections.
What supports the fibroblast-rich Seed?
Hair-follicle dermal precursors show neural-crest-like and multi-lineage properties in laboratory research, and meniscus contains fibroblast-like cell populations. No direct human study shows that the chair-side hair-follicle micrograft preparation regenerates meniscus.
Does the selected collagen scaffold have direct meniscus evidence?
We did not locate direct clinical evidence for ChondroFiller in a non-operative meniscus treatment. Its product-specific clinical evidence concerns articular cartilage. Evidence for other collagen meniscus implants supports the general scaffold principle only.
Can NanoAMi replace meniscus stitches?
No. It may be considered for selected stable, viable damage where mechanical fixation is not required. A displaced tear, root tear or unstable repairable tear remains a structural problem and may require surgery.
Still have more specific concerns?
Free Discovery CallOptions that our doctors may discuss include NanoACi, ChondroFiller, Mytocel MSK, joint replacement, established conservative care or surgery, depending on examination and imaging.
Discuss the evidence, limitations and alternatives
Professor Lee can explain how the evidence applies to your meniscus, where the rationale is extrapolated and whether this pathway is proportionate.